Leigh Ball, MD
Internal Medicine · Saint Louis, MONPI 1134583925
Payments from drug & device makers
Across 86 payments — averaging $23.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$626
- Novo Nordisk$360
- Lilly USA, LLC$150
- Axsome Therapeutics, Inc.$144
- Inspire Medical Systems, Inc.$111
- Amgen$86
- plus $563 from 16 others
What the payments were for
- Food & beverage$2,02799%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 14 | $626 |
| Novo Nordisk | 21 | $360 |
| Lilly USA, LLC | 8 | $150 |
| Axsome Therapeutics, Inc. | 3 | $144 |
| Inspire Medical Systems, Inc. | 3 | $111 |
| Amgen | 4 | $86 |
| AbbVie | 4 | $68 |
| AstraZeneca | 4 | $65 |
| UCB, Inc. | 3 | $64 |
| Novartis | 3 | $59 |
| Daiichi Sankyo Inc. | 3 | $49 |
| Johnson & Johnson | 3 | $47 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Bayer | 2 | $29 |
| GSK | 2 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Neos Therapeutics, LP | 1 | $21 |
| Exact Sciences | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XYWAV$145
How this compares
$2,039 in reported general payments places this provider in the 80th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 111 | $133,041 |
| EliquisApixaban | 91 | $89,404 |
| IngrezzaValbenazine Tosylate | 12 | $88,616 |
| NuedextaDextromethorphan Hbr/Quinidine | 26 | $44,260 |
| RybelsusSemaglutide | 14 | $33,764 |
| MounjaroTirzepatide | 29 | $32,442 |
| TrulicityDulaglutide | 20 | $31,020 |
| JanuviaSitagliptin Phosphate | 18 | $28,045 |
| XareltoRivaroxaban | 22 | $24,796 |
| NucyntaTapentadol Hcl | 13 | $22,963 |
| MyrbetriqMirabegron | 16 | $22,681 |
| FarxigaDapagliflozin Propanediol | 12 | $19,422 |
| EntrestoSacubitril/Valsartan | 13 | $16,873 |
| JardianceEmpagliflozin | 11 | $13,550 |
| BelsomraSuvorexant | 16 | $13,481 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $360 | $166,806125 claims |
| Lilly USA, LLCMounjaro, Trulicity | $150 | $63,46149 claims |
| GSKIncruse Ellipta, Breo Ellipta, Arexvy | $27 | $25,83052 claims |
| Johnson & JohnsonXarelto | $47 | $24,79622 claims |
| AstraZenecaFarxiga | $65 | $19,42212 claims |
| NovartisEntresto | $59 | $16,87313 claims |
| AbbVieLinzess | $68 | $8,36215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Saint Louis
- Michael ReschakSaint Louis$3.1M
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Hany SalamaSaint Louis$279K
- Lauren LevineSaint Louis$264K
- Brij VaidSaint Louis$213K
- Vinay KamatSaint Louis$191K
- Tracy NorfleetSaint Louis$132K
- Paul OlivoSaint Louis$98K
- Priyanka RavalSaint Louis$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.